Harvard Business Review

NOVEMBER 22, 2010

But the focus was squarely on "energy saving, environmental protection, and the low-carbon economy" with other emerging areas — infotech, biotech, and modern materials — taking a distinctly secondary role. The theme of the big event was "Technology-led Transition and Innovation-driven Development," which sounds broad.

15

15

Harvard Business Review

MAY 16, 2011

True collaboration always has open-ended elements — ranging from precisely how new innovations will be implemented, to how products will fare in the market, and even to what priorities partners will pursue in the face of changes in the environment. This landscape is evolving rapidly, in ways not even Google could foresee.

19

19

Harvard Business Review

AUGUST 24, 2015

Some argue that the low-hanging fruit has already been picked: the IT revolution has run its course and other new technologies like biotech have yet to make a major impact on our lives. A spirited debate is now under way on the future of technology and productivity.

15

15

Harvard Business Review

NOVEMBER 22, 2010

But the focus was squarely on "energy saving, environmental protection, and the low-carbon economy" with other emerging areas — infotech, biotech, and modern materials — taking a distinctly secondary role. The theme of the big event was "Technology-led Transition and Innovation-driven Development," which sounds broad.

15

15

Harvard Business Review

SEPTEMBER 12, 2016

Suppliers of scientific goods to a biotech company will want to hear from procurement officers and the scientists who use the goods. So it launched Project Speed, which gave the service engineering team authority to implement temporary fixes in the field until Cummins could get a permanent solution into production.

12

12

Harvard Business Review

MAY 15, 2018

For example, many business service firms are prompting professionals who serve customers in similar industries such as insurance or biotech to meet informally and share sector insights and leads. Set up “communities of practice” or business development initiatives to help share expertise or resources.

15

15

Harvard Business Review

SEPTEMBER 14, 2011

In doing so, Dr Reddy's strengthens its core generic drugs business and boosts the custom manufacturing services it provides to Big Pharma and nimble biotech startups. Dr Reddy's plan is to leverage Chirotech's scientific capabilities to optimize drug development processes, thus lowering manufacturing costs and speeding time-to-market.

11

11

Harvard Business Review

JUNE 4, 2018

” Yet another example of a business/education partnership is Shire, a biotech company with U.S. “Our grads are not only being hired by Shire, which now has about 15 of them, but also other biotech companies in the region. . We were founded in 1885, to work with industry, and that is still a core mission for Georgia Tech.”

8

8

Harvard Business Review

SEPTEMBER 30, 2016

My colleague Tomasz Obloj, of HEC Paris, and I recently examined the effects of an awards program implemented at a European bank selling small consumer loans. For years, large pharmaceutical firms purchased small biotech firms with promises to keep their “entrepreneurial rewards” intact.

13

13

Harvard Business Review

FEBRUARY 20, 2018

Led in part by Prime Minister Shinzo Abe and his “Abenomics,” the country has implemented widespread changes in health-related policies, regulations, and laws. To demonstrate the reality of the changes, Novick remembers how some foreign companies were once intimidated by Japanese pharmaceutical and biotech regulators.

8

8

Harvard Business Review

AUGUST 24, 2017

Lawyers are at the helms of banks, biotech companies, high-tech firms, internet startups, and retail outfits, as well as utilities and pharmaceuticals. CEOs with legal training tended to implement more-cautious earnings management policies, especially in industries with high litigation risk, like pharmaceuticals.

8

8

Harvard Business Review

OCTOBER 30, 2017

Our analysis of Pitchbook Data shows that more than $200 billion has been poured into health care venture capital, mostly in biotech, pharma, and devices where advances typically make health care more sophisticated — and expensive.

8

8